Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/11/2025

Initial Treatment for Cryoglobulinemia

Treatment Algorithm Based on Disease Severity

  • For patients with HCV-related cryoglobulinemia, antiviral therapy aimed at HCV eradication should be considered the first-line therapeutic option, particularly in mild to moderate disease, as recommended by the American Autoimmunity Association 1, 2
  • First-line therapy should be directed at the underlying cause, particularly HCV eradication using interferon-free direct-acting antiviral regimens in HCV-related cases, with a strength of evidence based on expert consensus and observational studies 1, 2, 3
  • For mild symptoms refractory to antiviral therapy, colchicine can be considered as a supportive treatment, with a low strength of evidence due to limited studies 1, 4
  • Low-antigen-content diet can be considered as supportive treatment in all symptomatic patients, although the evidence quality is limited 1, 4

Treatment Based on Specific Organ Involvement

  • For severe/rapidly progressive glomerulonephritis: immunosuppression is the first-line intervention, with rituximab showing 70-90% renal response rates in cryoglobulinemic nephritis, as recommended by the Italian Group for the Study of Cryoglobulinemia (GISC) 3, 5
  • Typical regimen includes high-dose glucocorticoids (0.5-1 mg/kg/day with tapering) often preceded by methylprednisolone pulses (10-15 mg/kg), with a moderate strength of evidence based on observational studies 3, 5
  • Mycophenolate mofetil can be an alternative to cyclophosphamide for 6 months, with a low strength of evidence due to limited studies 3, 5
  • Plasmapheresis is the first-line treatment for hyperviscosity syndrome, with a high strength of evidence based on expert consensus and observational studies 6, 1
  • A 3-4 liter plasma exchange can lower plasma IgM levels by approximately 60-75%, with a moderate strength of evidence based on observational studies 7

Important Considerations and Caveats

  • Antiviral therapy may be insufficient to rapidly control severe disease manifestations and should be combined with or preceded by immunosuppressive therapy in these cases, with a moderate strength of evidence based on expert consensus and observational studies 1, 3
  • Rituximab may cause a flare of cryoglobulinemia in patients with high cryoglobulin levels; in such cases, plasmapheresis should precede rituximab therapy, with a low strength of evidence due to limited studies 3, 5
  • Chronic treatment with low glucocorticoid doses should be avoided whenever possible due to side effects, with a high strength of evidence based on expert consensus and observational studies 6, 1
  • Careful monitoring of drug side effects and their impact on viral replication and liver function is essential, with a moderate strength of evidence based on expert consensus and observational studies 1, 4